Physician profile
David Brigham
NPI 1780605212
$633.77
in general payments reported to CMS, 2019-2025
16 companies · $20.46 in 2025
The $20.46 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $86.21 · 2021: $171 · 2022: $73.35 · 2023: $20.38 · 2025: $20.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.88 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $80.17 | 2019 | |
| Biotissue Holdings INC. | $62.33 | 2019-2020 | |
| Allergan, INC. | $55.01 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $46.74 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $42.71 | 2019-2021 | |
| Alcon Vision LLC | $38.84 | 2019-2021 | |
| Horizon Therapeutics Plc | $37.65 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $32.21 | 2019 | |
| Abbvie INC. | $23.97 | 2022 | |
| Amgen INC. | $20.46 | 2025 | Tepezza |
| Thea Pharma INC. | $20.38 | 2023 | |
| Rxsight INC | $18.32 | 2022 | |
| Shire North American Group INC | $17.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.90 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.